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icroparticles,
ebris That Hurts*
erard Pasterkamp, MD, PHD, FESC,†
ominique de Kleijn, PHD‡
trecht, the Netherlands
icroparticles (MPs) are fragments of cell membranes
eleased from stimulated or apoptotic cells that have long
een considered innocent remnants of cell destruction.
vidence is accumulating, however, that the circulating and
issue-derived MPs may elicit a strong thrombogenic and
nflammatory response (1). In addition to MPs, activated
ells can also release smaller vesicle-denominated exosomes
hat are relatively unexplored in the research area of vascular
iology (2).
Circulating MPs are being explored as a potential
ource for biomarker discovery. Platelet MPs have been
ssociated with clinically evident atherosclerotic disease
n diabetes type II patients (3), and leukocyte-derived
Ps are predictive of subclinical atherosclerosis in
symptomatic patients (4).
See page 1302
Experimental and clinical data consistently point to a
ausal role for MPs in atherosclerosis development and
rogression. Recent reports revealed their contribution to
emostatic and inflammatory responses, vascular remodel-
ng and angiogenesis, cell survival, and apoptosis, well-
nown processes involved in atherothrombosis. Platelets
onstitute the main source of circulating procoagulant MPs
nder many pathophysiological situations. These MPs en-
ompass functional membrane or cytoplasmic effectors that
lay an important role in platelet aggregation and harbor
ffectors like glycoprotein IIb/IIIa, glycoprotein Ib, von
illebrand factor, arachidonic acid, and thromboxane A2
1). The procoagulant MPs are less prevalent in healthy
ndividuals. Recently, the presence of functionally active
issue factor in platelets has been reported by several groups,
hich could play an important role in the initiation of
hrombus formation (5). Although the exact source of this
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nstitute of the Netherlands, Utrecht, the Netherlands.latelet-derived tissue factor is unknown, one of the con-
epts is that tissue factor is taken up in the form of
irculating MPs potentially derived from monocytes.
A role for MPs in inflammatory responses in the vascular
all has been suggested. Plaque-derived MPs enhance the
ell surface processing of the TACE/ADAM17 substrate
umor necrosis factor and the receptor TNFR-1, suggesting
hat MPs could regulate the inflammatory balance in the
therosclerotic lesion (6).
In this issue of the Journal, Leroyer et al. (7) report
nother mechanism by which MPs can contribute to a local
nflammatory response and subsequent plaque destabiliza-
ion. They show that MPs that are isolated from human
therosclerotic lesions express CD40 ligand (CD40L). In an
xperimental setup, they nicely demonstrate that plaque-
erived CD40L particles hide proangiogenic properties
n vitro and in vivo. It has been shown previously that
latelet-derived MPs induce angiogenesis in vitro and
n vivo (8). These studies pointed to a beneficial role for
irculating MPs in revascularization after myocardial is-
hemia. Leroyer et al. (7) show that CD40 MPs with
ngiogenic properties are associated with plaques from
atients suffering from symptomatic carotid artery disease,
nd they propose a role for plaque neovascularization, a
laque-destabilizing feature.
CD40-CD40L interactions play a central role in athero-
clerosis progression. In mice studies, inhibition of CD40L
ignaling results in a significant decrease of plaque develop-
ent (9,10). CD40 and CD40L are coexpressed by most, if
ot all, cells that are known to play a role in atherosclerotic
isease such as endothelial cells, smooth muscle cells,
acrophages, and platelets. CD40L on platelets is rapidly
ranslocated onto the cell surface after activation. Interest-
ngly, more than 95% of the circulating CD40L is derived
rom platelets (11). Platelet-derived CD40L has been ex-
mined as a biomarker for unstable coronary artery disease
nd stroke, but it is still debated whether increased circu-
ating CD40L levels reflect the local vascular thrombus
ormation or are more likely a consequence of the clinical
vent.
Literature consistently reports that platelets are the main
ource of functionally active MPs and circulating CD40L.
urprisingly, Leroyer et al. (7) describe that plaque-derived
Ps are mainly of leucocyte origin and do not originate
rom platelets. Moreover, in atherosclerotic plaques,
D40L was not observed on platelet-derived MPs. This is
ather unexpected since intraplaque bleeding is regularly
bserved in carotid plaques, and the presented study reports
he presence of erythrocyte-derived particles in atheroscle-
otic lesions. The authors did demonstrate that the angio-
enic properties of plaque- and leucocyte-derived MPs were
ot shared by circulating MPs, which are more likely
latelet MPs, when samples were compared that were
btained from the identical patients.
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October 14, 2008:1312–3 Microparticles and CD40LThe reported evidence supports the concept that in-
raplaque apoptosis results in MP accumulation and subse-
uent endothelial cell proliferation and intraplaque neovas-
ularization, and will further stimulate the search for
nflammatory pathways that play a dominant role in athero-
clerotic plaque destabilization. Whether CD40L MPs
re dominant players in lesion progression and thrombosis
emains to be elucidated. For instance, it is unclear to what
xtent MP-associated CD40L contributes to lesion progres-
ion compared with other cell-based sources of CD40L. In
ddition, the absence of an effect on endothelial cell prolif-
ration using MPs from the circulation may conflict with
revious reports (8), since a proangiogenic effect has been
escribed for blood-derived platelet MPs. As mentioned
arlier, the complete lack of platelet-derived MPs in
laques, while platelets are the dominant source of
D40L MPs in the circulation, is rather unexpected.
The implications of the presented data for pathogenesis
esearch are evident. However, it is more difficult to indicate
he clinical implications of the presented research. First,
Ps were obtained from a relatively small cohort of
ymptomatic and asymptomatic patients. Effects on MP-
elated functions by medication use, established risk factors,
r delay between symptoms and surgery could, therefore,
ot be taken into account. Second, it could be suggested
hat blocking CD40L might stabilize plaques by inhibition
f plaque neovascularization. However, the use of CD40L
ntibodies may result in unwanted complications that could
e detrimental in patients suffering from cardiovascular
isease since human trials revealed an increase in thrombotic
omplications when a monoclonal antibody against CD40L
as administered (12). Third, tissue MPs may be difficult to
arget therapeutically. However, circulating MPs are con-
idered a therapeutic target in cardiovascular disease (13).
ecent patents regarding circulating MPs and exosomes are
elated to their procoagulant potential.
In summary, MPs should not be appreciated as innocent
ebris since they may hide procoagulant and inflammatory
ctivity that may influence atherothrombosis and lesion
rogression. The different functional characteristics of cir-
K
mulating MPs and atherosclerotic plaque-derived MPs are
ntriguing and deserve more detailed research.
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